A plethora of targets, a paucity of drugs: Progress towards the development of novel chemotherapies for human African trypanosomiasis

Expert Review of Anti-Infective Therapy

Volumn 1, Issue 1, 2003, Pages 157-165

  Naula, Christina ^a   Burchmore, Richard ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Acidocalcisome; Cell cycle; Chemotherapy; Drug target; Glycolysis glycosome; Human African trypanosomiasis; Kinetoplast

Indexed keywords

2 AMINO 5 (1 METHYL 5 NITRO 2 IMIDAZOLYL) 1,3,4 THIADIAZOLE; ALSTERPAULLONE; ANTITRYPANOSOMAL AGENT; BISPHOSPHONIC ACID DERIVATIVE; CARBOHYDRATE; CYCLIN DEPENDENT KINASE INHIBITOR; DB 289; DIAMIDE; EFLORNITHINE; FLAVOPIRIDOL; IMIDAZOLE DERIVATIVE; LIPID; MELARSOPROL; NIFURTIMOX; NITROFURAN DERIVATIVE; ORNITHINE DERIVATIVE; PENTAMIDINE DERIVATIVE; PENTAMIDINE ISETHIONATE; PROTEIN; SURAMIN; UNCLASSIFIED DRUG;

AFRICA; AFRICAN TRYPANOSOMIASIS; BLOOD BRAIN BARRIER; BRAIN DISEASE; CARBOHYDRATE METABOLISM; CELL CYCLE; CELL ORGANELLE; CHEMOTHERAPY; CLINICAL TRIAL; DRUG MARKETING; DRUG PENETRATION; DRUG TARGETING; ECONOMIC ASPECT; HOST PARASITE INTERACTION; HUMAN; KINETOPLAST; LIPID METABOLISM; OXIDATIVE STRESS; PROTEIN MODIFICATION; REVIEW; SIDE EFFECT; TRYPANOSOMA;

EID: 2942622470     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.1.1.157     Document Type: Review

References (80)

1. WHO. Control & surveillance of African trypanosomiasis. Report of a WHO expert committee. 881, 1-114 (1998).
2. Legros D, Ollivier G, Gastellu-Etchegorry M et al. Treatment of human African trypanosomiasis-present situation and needs for research and development. Lancet Infect. Dis. 2, 437-440 (2002).
3. Burchmore RJ, Ogbunude PO, Enanga B, Barrett MP. Chemotherapy of human African trypanosomiasis. Curr. Pharm. Des 8, 256-267 (2002).
4. Enanga B, Burchmore RJ, Stewart ML, Barrett MP. Sleeping sickness and the brain. Cell Mol. Life Sci. 59, 845-858 (2002).
5. Matovu E, Seebeck T, Enyaru JC, Kaminsky, R. Drug resistance in Trypanosoma brucei spp., the causative agents of sleeping sickness in man and nagana in cattle. Microbes Infect. 3, 763-770 (2001).
6. Matovu E, Enyaru JC, Legros D, Schmid, C, Seebeck, T, Kaminsky R. Melarsoprol refractory T. b. gambiense from Omugo, north-western Uganda. Trop. Med. Int. Health 6, 407-411 (2001).
7. Barry JD. The molecular biology of African trypanosomes. Trop. Dis. Bull. 83, R1-R25 (1986).
8. Pepin J, Milord F, Khonde AN et al. Risk factors for encephalopathy and mortality during melarsoprol treatment of Trypanosoma brucei gambiense sleeping sickness. Trans. R. Soc. Trop. Med. Hyg. 89, 92-97 (1995).
9. Matovu E, Geiser F, Schneider V et al. Genetic variants of the TbAT1 adenosine transporter from African trypanosomes in relapse infections following melarsoprol therapy. Mol. Biochem. Parasitol. 117, 73-81 (28-9-2001).
10. Pepin J, Milord F. The treatment of human African trypanosomiasis. Adv. Parasitol. 33, 1-47 (1994).
11. McCann PP, Pegg AE. Ornithine decarboxylase as an enzyme target for therapy. Pharmacol. Ther. 54, 195-215 (1992).
12. Pepin J, Milord F, Meurice F, Ethier L, Loko L, Mpia B. High-dose nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness: an open trial in central Zaire. Trans. R. Soc. Trop. Med. Hyg. 86, 254-256 (1992).
13. Hannaert V, Saavedra E, Duffieux F et al. Plant-like traits associated with metabolism of Trypanosoma parasites. Proc. Natl. Acad. Sci. USA 100, 1067-1071 (2003).
14. Seyfang A, Duszenko M. Specificity of glucose-transport in trypanosoma-brucei-effective inhibition by phloretin and cytochalasin-b. Eur. J. Biochem. 202, 191-196 (1991).
15. Barrett MP, Tetaud E, Seyfang A, Bringaud F, Baltz T. Trypanosome glucose transporters. Mol. Biochem. Parasitol. 91, 195-205 (1998).
16. Bakker BM, Walsh MC, Ter Kuile BH et al. Contribution of glucose transport to the control of the glycolytic flux in Typanosoma brucei. Proc. Natl. Acad. Sci. USA 96, 10098-10103 (1999).
17. Bressi JC, Verlinde CL, Aronov AM et al. Adenosine analogues as selective inhibitors of glyceraldehyde-3-phosphate dehydrogenase of Typanosomatidae via structure-based drug design. J. Med. Chem. 44, 2080-2093 (2001).
18. Lakhdar-Ghazal F, Blonski C, Willson M, Michels P, Perie J. Glycolysis and proteases as targets for the design of new antitrypanosome drugs. Curr. Top. Med. Chem. 2,439-456 (2002).
19. Blattner J, Heffert S, Michels P, Clayton C. Compartmentation of phosphoglycerate kinase in Trypanosoma brucei plays a critical role in parasite energy metabolism. Proc. Natl Acad. Sci. USA 95, 11596-11600 (1998).
20. Furuya T, Kessler P, Jardim A, Schnaufer A, Crudder C, Parsons M. Glucose is toxic to glycosome-deficient trypanosomes. Proc. Natl Acad. Sci. USA 99, 14177-14182 (2002).
21. Wiemer EA, Ter Kuile BH, Michels PA, Opperdoes FR. Pyruvate transport across the plasma membrane of the bloodstream form of Trypanosoma brucei is mediated by a facilitated diffusion carrier. Biochem. Biophys. Res. Commun. 184, 1028-1034 (1992).
22. Wiemer EA, Michels PA, Opperdoes FR. The inhibition of pyruvate transport across the plasma membrane of the bloodstream form of Trypanosoma brucei and its metabolic implications. Biochem. J. 312 (Pt 2), 479-484 (1995).
23. Chaudhuri M, Ajayi W, Hill GC. Biochemical and molecular properties of the Trypanosoma brucei alternative oxidase. Mol. Biochem. Parasitol. 95, 53-68 (1998).
24. Barrett MP. The pentose phosphate pathway and parasitic protozoa. Parasitol. Today 13, 11-16 (1997).
25. Roper JR, Guther ML, Milne KG, Ferguson MA. Galactose metabolism is essential for the African sleeping sickness parasite Trypanosoma brucei. Proc. Natl. Acad. Sci. USA 99, 5884-5889 (2002).
26. Patnaik PK, Field MC, Menon AK, Cross GAM, Yee MC, Bütikofer P. Molecular species analysis of phospholipids from Trypanosoma brucei bloodstream and procyclic forms. Mol. Biochem. Parasitol. 58, 97-106 (1993).
27. Croft SL, Snowdon D, Yardley V. The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J. Antimicrob. Chemother. 38, 1041-1047 (1996).
28. Morita YS, Paul KS, Englund PT. Specialized fatty acid synthesis in African trypanosomes: myristate for CPI anchors. Science 288, 140-143 (2000).
29. Morita YS, Englund PT. Fatty acid remodeling of glycosyl phosphatidylinositol anchors in Trypanosoma brucei: incorporation of fatty acids other than myristate. Mol. Biochem. Parasitol. 115, 157-164 (2001).
30. Martin MB, Grimley JS, Lewis JC et al. Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii and Plasmodium falciparum: a potential route to chemotherapy. J. Med. Chem. 44, 909-916 (2001).
31. Martin MB, Sanders JM, Kendrick H et al. Activity of bisphosphonates against Trypanosoma brucei rhodesiense. J. Med. Chem. 45, 2904-2914 (2002).
32. Sun J, Qian Y, Hamilton AD, Sebti SM. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts. Oncogene 16, 1467-1473 (1998).
33. Buckner FS, Yokoyama K, Nguyen L et al. Cloning, heterologous expression and distinct substrate specificity of protein farnesyltransferase from Trypanosoma brucei. J. Biol. Chem. 275, 21870-21876 (2000).
34. Yokoyama K, Trobridge P, Buckner FS, Van Voorhis WC, Stuart KD, Gelb MH. Protein farnesyltransferase from Trypanosoma brucei - A heterodimer of 61- and 65-kDa subunits as a new target for antiparasite therapeutics. J. Biol. Chem. 273, 26497-26505 (1998).
35. Yokoyama K, Trobridge P, Buckner FS et al. The effects of protein farnesyltransferase inhibitors on trypanosomatids: inhibition of protein farnesylation and cell growth. Mol. Biochem. Parasitol. 94, 87-97 (1998).
36. Clerici F, Gelmi ML, Yokoyama K et al. Isothiazole dioxides: synthesis and inhibition of Trypanosoma brucei protein farnesyltransferase. Bioorg. Med. Chem. Lett. 12, 2217-2220 (2002).
37. Klingbeil MM, Motyka SA, Englund PT. Multiple mitochondrial DNA polymerases in Trypanosoma brucei. Mol. Cell 10, 175-186 (2002).
38. Morris JC, Drew ME, Klingbeil MM et al. Replication of kinetoplast DNA: an update for the new millennium. Int. J. Parasitol. 31, 453-458 (2001).
39. Wang Z, Englund PT. RNA interference of a trypanosome topoisomerase II causes progressive loss of mitochondrial DNA. EMBO J. 20, 4674-4683 (2001).
40. Nenortas EC, Bodley AL, Shapiro TA. DNA topoisomerases: a new twist for antiparasitic chemotherapy? Biochimica et Biophysica Acta: Gene Struct. Expression 1400, 349-354 (1998).
41. Schnaufer A, Domingo GJ, Stuart K. Natural and induced dyskinetoplastic trypanosomatids: how to live without mitochondrial DNA. Int. J. Parasitol. 32, 1071-1084 (2002).
42. Schnaufer A, Panigrahi AK, Panicucci B et al. An RNA ligase essential for RNA editing and survival of the bloodstream form of Trypanosoma brucei. Science 291, 2159-2162 (2001).
43. Dumas C, Ouellette M, Tovar J et al. Disruption of the trypanothione reductase gene of Leishmania decreases its ability to survive oxidative stress in macrophages. EMBO J. 16,2590-2598 (1997).
44. Phillips C, Dohnalek J, Gover S, Barrett MP, Adams MJ. A 2.8 A resolution structure of 6-phosphogluconate dehydrogenase from the protozoan parasite Trypanosoma brucei: comparison with the sheep enzyme accounts for differences in activity with coenzyme and substrate analogues. J. Mol. Biol. 282, 667-681 (1998).
45. Schmidt A, Krauth-Siegel RL. Enzymes of the trypanothione metabolism as targets for antitrypanosomal drug development. Curr. Top. Med. Chem. 2, 1239-1259 (2002).
46. Bouteille B, Marie-Daragon A, Chauviere G et al. Effect of megazol on Trypanosoma brucei brucei acute and subacute infections in Swiss mice. Acta Trop. 60, 73-80 (1995).
47. Moreno SN. The reductive metabolism of nifurtimox and benznidazole in Crithidia fasciculata is similar to that in Trypanosoma cruzi. Comp Biochem. Physiol C. 91, 321-325 (1988).
48. Maya JD, Repetto Y, Agosin M et al. Effects of nifurtimox and benznidazole upon glutathione and trypanothione content in epimastigote, trypomastigote and amastigote forms of Trypanosoma cruzi. Mol. Biochem. Parasitol. 86, 101-106 (1997).
49. Ferreira RC, Ferreira LC. CL 64,855, a potent anti Trypanosoma cruzi drug, is also mutagenic in the Salmonella/microsome assay. Mem. Inst. Oswaldo Cruz 81, 49-52 (1986).
50. Nurse P. A long twentieth century of the cell cycle and beyond. Cell 100, 71-78 (2000).
51. Knockaert M, Greengard P, Meijer L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol. Sci. 23, 417-425 (2002).
52. Hammarton TC, Mottram JC, Doerig C. The cell cycle of parasitic protozoa: potential for chemotherapeutic exploitation. 91-101 (2002).
53. Mottram JC, Smith G. A family of trypanosome cdc2-related protein kinases. Gene 162, 147-152 (1995).
54. Mottram JC. cdc2-related protein kinases and cell cycle control in trypanosomatids. Parasitol. Today 10, 253-257 (1994).
55. Hassan P, Fergusson D, Grant KM, Mottram, J C. The CRK3 protein kinase is essential for cell cycle progression of Leishmania mexicana. Mol. Biochem. Parasitol. 113, 189-198 (2001).
56. Xiao Z, Waters NC, Woodard CL, Li Z, Li PK. Design and synthesis of Pfmrk inhibitors as potential antimalarial agents. Bioorg. Med. Chem. Lett. 11, 2875-2878 (2001).
57. Docampo R, Moreno SNJ. The acidocalcisome. Mol. Biochem. Parasitol. 114, 151-159 (2001).
58. McIntosh MT, Vaidya AB. Vacuolar type H+ pumping pyrophosphatases of parasitic protozoa. Int. J. Parasitol. 32, 1-14 (2002).
59. Lemercier G, Dutoya S, Luo S et al. A vacuolar-type H+-pyrophosphatase governs maintenance of functional acidocalcisomes and growth of the insect and mammalian forms of Trypanosoma brucei. J. Biol. Chem. 277, 37369-37376 (2002).
60. Drozdowicz YM, Shaw M, Nishi M et al. Isolation and characterization of TgVP1, a Type I vacuolar H+-translocating pyrophosphatase from Toxoplasma gondii. The dynamics of its subcellular localization and the cellular effects of a diphosphonate inhibitor. J. Biol. Chem. 278, 1075-1085 (2003).
61. Bakker BM, Westerhoff HV, Opperdoes FR, Michels PAM. Metabolic control analysis of glycolysis in trypanosomes as an approach to improve selectivity and effectiveness of drugs. Mol. Biochem. Parasitol. 106, 1-10 (2000).
62. Hasne M, Barrett MP. Drug uptake via nutrient transporters in Trypanosoma brucei. J. Appl. Microbiol. 89, 697-701 (2000).
63. Wiemer EAC, Michels PAM, Opperdoes FR. The inhibition of pyruvate transport across the plasma membrane of the bloodstream form of Trypanosoma brucei and its metabolic implications. Biochem. J. 312, 479-484 (1995).
64. Wallace LJ, Candlish D, De Koning HP. Different substrate recognition motifs of human and trypanosome nucleobase transporters. Selective uptake of purine antimetabolites. J. Biol. Chem. 277, 26149-26156 (2002).
65. Hofer A, Steverding D, Chabes A, Brun R, Thelander L. Trypanosoma brucei CTP synthetase: A target for the treatment of African sleeping sickness. Proc. Natl Acad. Sci. USA 98, 6412-6416 (2001).
66. Miles RW, Tyler PC, Evans GB, Furneaux RH, Parkin DW, Schramm VL. Iminoribitol transition state analogue inhibitors of protozoan nucleoside hydrolases. Biochemistry 38, 13147-13154 (1999).
67. Benson TJ, Mckie JH, Garforth J, Borges A, Fairlamb AH, Douglas KT. Rationally designed selective inhibitors of trypanothione reductase - phenothiazines and related tricyclics as lead structures. Biochem. J. 286, 9-11 (1992).
68. Krieger S, Schwarz W, Ariyanayagam MR, Fairlamb AH, Krauth-Siegel RL, Clayton C. Trypanosomes lacking trypanothione reductase are avirulent and show increased sensitivity to oxidative stress. Mol. Microbiol. 35, 542-552 (2000).
69. Bacchi CJ, Goldberg B, Garofalo-Hannan J, Rattendi D, Lyte P, Yarlett N. Fate of soluble methionine in African trypanosomes: Effects of metabolic inhibitors. Biochem. J. 309, 737-743 (1995).
70. Mccann PP, Bacchi CJ, Clarkson AB et al. Inhibition of polyamine biosynthesis by α-difluoromethylornithine in african trypanosomes and pneumocystis- carinii as a basis of chemotherapy - biochemical and clinical aspects. Am. J. Trop. Med. Hyg. 35, 1153-1156 (1986).
71. Bacchi CJ, Yarlett N. Polyamine metabolism as chemotherapeutic target in protozoan parasites. Mini. Rev. Med. Chem. 2, 553-563 (2002).
72. Chowdhury SF, Di Lucrezia R, Guerrero RH et al. Novel inhibitors of Leishmanial dihydrofolace reductase. Bioorg. Med. Chem. Lett. 11, 977-980 (2001).
73. Ho CK, Shuman S. Trypanosoma brucei RNA triphosphatase. Antiprotozoal drug target and guide to eukaryotic phylogeny. J. Biol. Chem. 276, 46182-46186 (2001).
74. Stiles JK, Hicock PI, Shah PH, Meade JC. Genomic organization, transcription, splicing and gene regulation in Leishmania. Ann. Trop. Med. Parasitol. 93, 781-807 (1999).
75. Nagamune K, Nozaki T, Maeda Y et al. Critical roles of glycosylphosphatidylinositol for Trypanosoma brucei. Proc. Natl. Acad. Sci. USA 97, 10336-10341 (2000).
76. Ferguson MAJ, Brimacombe JS, Brown JR et al. The GPI biosynthetic pathway as a therapeutic target for African sleeping sickness. Biochim. Biophys. Acta Mol. Basis Dis. 1455, 327-340 (1999).
77. Nkemgu-Njinkeng J, Rosenkranz V, Wink M, Steverding D. Antitrypanosomal activities of proteasome inhibitors. Antimicrob. Agents Chemother. 46, 2038-2040 (2002).
78. Troeberg L, Morty RE, Pike RN et al. Cysteine proteinase inhibitors kill cultured bloodstream forms of Trypanosoma brucei brucei. Exp. Parasitol. 91, 349-355 (1999).
79. Troeberg L, Chen X, Flaherty TM et al. Chalcone, acyl hydrazide and related amides kill cultured Trypanosoma brucei brucei. Mol. Med. 6, 660-669 (2000).
80. Zoraghi R, Seebeck T. The cAMP-specific phosphodiesterase TbPDE2C is an essential enzyme in bloodstream form Trypanosoma brucei. Proc. Natl. Acad. Sci. USA 99, 4343-4348 (2002).